Table 1 Clinical characteristics of DCM and ICM cohorts
Characteristics | DCM (n = 37) | ICM (n = 13) | p-value |
|---|---|---|---|
Male sex, n (%) | 30 (81) | 10 (77) | 0.71 |
Age at transplant | 49 ± 13 | 56 ± 4 | 0.10 |
Race | |||
 Caucasian, n (%) | 31 (84) | 13 (100) | 0.32 |
 Black/African American, n (%) | 3(8) | 0 (0) | 0.56 |
 unknown, n (%) | 3(8) | 0 (0) | 0.56 |
Ethnicity | |||
 Not Hispanic or Latino, n (%) | 26 (70) | 7 (54) | 0.32 |
 Hispanic or Latino, n (%) | 5 (14) | 1 (8) | 1.00 |
 unknown, n (%) | 6 (16) | 4 (31) | 0.42 |
NYHA | 3.3 ± 0.6 | 3.3 ± 1 | 0.67 |
aLVEF (%) | 18 ± 8 | 13 ± 5 | 0.09 |
Comorbidities | |||
 Coronary artery disease, n (%) | 4 (11) | 13 (100) | < 0.0001 |
 Diabetes mellitus, n (%) | 6 (16) | 8 (62) | 0.004 |
 Hyperlipidemia, n (%) | 8 (22) | 9 (69) | 0.005 |
aHistory of smoking, n (%) | 17 (49) | 8 (67) | 0.33 |
Hypertension, n (%) | 16 (43) | 8 (62) | 0.34 |
aBMI ≥ 30, n (%) | 5 (16) | 2(22) | 0.64 |
Medications | |||
 Inotropes, n (%) | 11 (30) | 3 (23) | 0.73 |
 Statins, n (%) | 10 (27) | 12 (92) | < 0.0001 |
 Antiarrhythmics, n (%) | 32 (86) | 12 (92) | 1.00 |
 Amiodarone, n (%) | 11 (30) | 3 (23) | 0.73 |
 Aspirin, n (%) | 8 (62) | 15 (41) | 0.22 |
 Beta Blockers, n (%) | 20 (54) | 8 (62) | 0.75 |
 ACE inhibitor, n (%) | 17 (46) | 8 (62) | 0.52 |
Device Therapy | |||
 ICD, n (%) | 32 (86) | 8 (62) | 0.10 |
 LVAD/BiVAD, n (%) | 16 (43) | 4 (31) | 0.52 |